Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESPIRE ATR-002 in hospitalized adults with COVID-19
NL-OMON50897Phase 2Withdrawn
- Sponsor
- Atriva Therapeutics
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing ATR-002 + standard of care with Placebo + standard of care (2 arms). Primary endpoint: Clinical severity status on 7-point ordinal scale at Day 15. Planned start Mar 2021; status: withdrawn.
02
Drugs
Zapnometinib
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NL-OMON50897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50897.